Defective adenoviruses and corresponding complementation lines

• US 6,040,174 A
• Filed: 01/26/1995
• Issued: 03/21/2000
• Est. Priority Date: 05/28/1993
• Status: Expired due to Term

• Current Assignee: Transgene S.A. (Compagnie Merieux Alliance SAS)
• Original Assignee: Transgene S.A. (Compagnie Merieux Alliance SAS)
• Inventors: Mehtali, Majid, Imler, Jean-Luc, Pavirani, Andrea
• Primary Examiner(s): Campell, Bruce R.
• Assistant Examiner(s): PRIEBE, SCOTT DAVID
• Application Number:
  US08/379,452
• Time in Patent Office: 1,881 Days
• Field of Search: 435/172.3, 435/240.1, 435/240.2, 435/240.21, 435/240.25, 435/320.1, 435/325, 435/455, 435/456, 511/2, 511/44, 424/93.21, 424/93.2, 530/350, 530/91.31
• US Class Current: 435/325
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 14/395 from Saccharomyces
• CPC Class Codes: C07K 14/4712 Cystic fibrosis
• CPC Class Codes: C07K 14/57 IFN-gamma
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/10352 relating to complementing cells and packaging systems for producing virus or viral particles
• CPC Class Codes: C12N 2710/10362 by genetic engineering
• CPC Class Codes: C12N 2830/00 Vector systems having a special element relevant for transcription
• CPC Class Codes: C12N 2830/002 inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
• CPC Class Codes: C12N 2830/15 chimeric enhancer/promoter combination
• CPC Class Codes: C12N 2830/60 from viruses
• CPC Class Codes: C12N 2840/20 translation of more than one cistron
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

Novel defective adenoviruses for the transfer and expression of an exogenous nucleotide sequence in a host cell or organism. The invention also relates to novel complementation lines and to the process for the preparation of these novel defective adenoviruses and their use in therapy and to a pharmaceutical composition containing same.

Claims

1. A complementation line comprising a complementation element for complementing in trans a defective adenoviral vector,

wherein said complementation element is either integrated into the chromosomal genome of said complementation line or inserted into an expression vector and said complementation element comprises a fragment of an adenoviral genome lacking an adenoviral 5'"'"'ITR and encoding an E1A gene product,

wherein the E1A gene product is expressed under control of:

a) an E1 promoter or a heterologous promoter when the complementation line is made from a human embryonic retinal cell or A549 cell;

b) an E1 promoter or a heterologous promoter when the complementation line is made by cotransfection of the expression vector comprising the complementation element and the defective adenoviral vector;

or

c) an inducible heterologous promoter.

2. The complementation line of claim 1 wherein said complementation element further comprises one or more fragments of an adenoviral genome encoding one or more gene products selected from the group consisting of E1B, E2 and E4 gene products.

3. The complementation line of claim 2 wherein said complementation element comprises said fragment of an adenoviral genome lacking an adenoviral 5'"'"'ITR and encoding E1A gene product and fragments of an adenoviral genome encoding the E1B early proteins.

4. The complementation line of claim 1 wherein said adenoviral genome is selected from the group consisting of canine, avian and human adenoviral genomes.

5. The complementation line of claim 4 wherein said genome is the human adenovirus type 5 genome.

6. The complementation line of claim 5 wherein said complementation element comprises the portion of the adenoviral genome of SEQ ID NO:

43 extending;

(i) from nucleotide 100 to nucleotide 5297;

(ii) from nucleotide 100 to nucleotide 4034;

or

(iii) from nucleotide 505 to nucleotide 4034.

7. The complementation cell line of claim 3 wherein said adenovirus is human adenovirus 5 and said fragments of an adenoviral genome encoding the E1B early proteins comprises at least the sequences lying between nucleotides 1634 and 3509 of SEQ ID NO:

43.

8. The complementation line of claim 5 wherein said complementation element comprises the portion of the E4 region of the genome of a human adenovirus type 5 extending from nucleotide 32800 to nucleotide 35826 of SEQ ID NO:

43.

9. The complementation line of claim 5 wherein said complementation element comprises the portion of the genome of a human adenovirus type 5 extending from nucleotide 505 to nucleotide 35826 of SEQ ID NO:

43.

10. The complementation line of claim 1 further comprising a gene coding for a selectable marker.

11. The complementation line of claim 1 wherein said complementation line is derived from a cell line selected from the group consisting of Vero, BHK, A549, MRC5 and WI 38.

12. The complementation line of claim 1 wherein said complementation line is derived from CHO cells.

13. The complementation line of claim 1 wherein said complementation line is derived from a human embryo retinal cell.

14. The complementation line of claim 1 wherein said complementation element comprises a fragment of an adenoviral genome lacking the 5'"'"'ITR, the encapsidation region, the promoter of the E1A region and the transcription termination signal of E1B and pIX transcription units.

15. The complementation line of claim 1 wherein the E1A gene product is expressed under the control of the promoter of the PGK gene of mouse.

16. The complementation line of claim 1 wherein the E1 gene product is placed under the control of a heterologous termination signal.

17. The complementation line of claim 16 wherein the heterologous termination signal is from a β

-globulin gene of rabbit.

18. A method for preparing an adenovirus particle containing an adenoviral vector which is defective for replication and which is derived from an adenoviral genome by deletion of at least all or part of the E1A region comprising the steps of:

(i) introducing a defective adenoviral vector into the complementation cell line of claim 1;

(ii) culturing the cell obtained in step (i) under suitable culture conditions for permitting the production of said adenovirus particle; and

(iii) recovering the adenoviral particle.

19. A complementation line comprising a complementation element for complementing in trans a defective adenoviral vector,

wherein said complementation element is either integrated into the chromosomal genome of said complementation line or inserted into an expression vector and said complementation element comprises a fragment of an adenoviral genome lacking an adenoviral 5'"'"'ITR and encoding an E1A gene product,

wherein the E1A gene product is expressed under control of:

a) an E1 promoter or a heterologous promoter when the complementation line is made from a human embryonic retinal cell or A549 cell;

or

b) an E1 promoter or a heterologous promoter when the complementation line is made by cotransfection of the expression vector comprising the complementation element and the defective adenoviral vector.